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Florence Wong
Division of Gastroenterology, Toronto General Hospital, University of Toronto, Toronto, Ontario, CanadaI ﬁrst met Prof. Sauerbruch at a Falk Symposium in February
1998. It was my ﬁrst trip to Bonn and my ﬁrst attendance at a
Falk Symposium. It was a little daunting, as I hardly knew anyone
there. I felt very dwarfed by the academic giants of the day in
portal hypertension/cirrhosis who were present. It was Prof.
Sauerbruch who made a point of putting me at ease, and made
sure that I was able to enjoy the meeting both scholastically
and socially. It was only afterwards that I realized Prof.
Sauerbruch was one of the notables in portal hypertension,
in addition to being very well known for his outstanding
contribution to the management of gall stone disease. From that
moment on, I have gotten to know Prof. Sauerbruch not only as a
well-respected scientist in the ﬁeld of portal hypertension, but
also as a superb mentor to his trainees, and a wonderful clinician
to his patients.
Prof. Sauerbruch received his undergraduate medical educa-
tion from the universities in Würzburg, Hamburg, Montpellier,
and Heidelberg. After an internship at the University of Heidel-
berg, he trained in Internal Medicine and Gastroenterology in
Heidelberg, Pforzheim and Munich from 1973 to 1979. He spent
his residency at the University of Munich, and then served as
Assistant Professor at the Medical Department II of the University
of Munich from 1983 to 1991. After a brief period as an Associate
Professor at the University of Munich, Medical Department II, he
received a full professorship at the University of Bonn and
became head of the Department for Internal Medicine I (General
Internal Medicine) in 1992. During that period, he dedicated part
of his time as Vice Dean, then Dean at the University of Bonn,
thus spanning his service into higher education.
His interest in gastroenterology started when he was a
student at the University of Heidelberg, when his teacher there
introduced him to do a research project on acute and chronic
hepatitis. His interest grew after he read a paper by B.S. Blumberg
[1] on the discovery of the Australian antigen as a marker of
serum hepatitis, or hepatitis B as we know it today. This led to
further research into the testing for the Australian antigen in
at-risk populations. He ventured into Africa and worked there
as a junior doctor, while searching for the Australian antigen
amongst the indigenous population. The work ultimately formed
the basis of his doctoral thesis [2,3]. His enthusiasm for
hepatology then became ﬁrmly established.
He recalls that his happiest time was when he spent tireless
hours in the 1980’s working with his mentor, Prof. GustavJournal of Hepatology 20
Received 5 May 2014; accepted 5 May 2014
E-mail address: ﬂorence.wong@utoronto.ca
Open access under CC BY-NC-ND license.Paumgartner at the University of Munich on the dissolution of
gallstones. Prof. Paumgartner is a life-long researcher on the
pathogenesis of gallstone disease. Although the use of ursodeoxy-
cholic acid is able to dissolve gall stones the process is painstak-
ingly slow. Prof. Sauerbruch, together with Dr Michael Delius and
Prof. Paumgartner, then devised the use of extracorporeal shock
wave lithotripsy as a non-surgical means of disintegrating gall-
stones [4] and bile duct stones [5]. This was ground-breaking in
the management of gall stones. This was subsequently extended
into the management of pancreatic stones [6]. I can still recall, as
a trainee in gastroenterology in Australia at that time, that the
various senior gastroenterologists at my hospital visited Munich
to learn the technique. Little did I know that one day, I would
have the privilege to get to know these eminent individuals
myself. Their work on gallstone dissolution was soon extended
to experiments on treatment of bile duct injuries. The insertion
of a biliary stent as its treatment was quite revolutionary at that
time [7]. Prof. Paumgartner also had a signiﬁcant impact on the
young Prof. Sauerbruch in many other ways. He taught him that14 vol. 61 j 469–471
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the best mode of scientiﬁc enquiries was to perform multi-center
randomized controlled trials. Thus we see many landmark papers
were generated from these randomized controlled trials [8,9].
Prof. Paumgartner also taught him how to write scientiﬁc papers,
enjoy literature and music. Most importantly, Prof. Paumgartner
set an example on how to nurture the younger generation of
medical students and trainees. The same attributes can easily
be found in Prof. Sauerbruch, who not only worries about the
academic achievements of his own trainees, but also their
personal development and well-being. So during my visit to Prof.
Sauerbruch in Bonn in 2004, he invited one of his research
fellows, Zhou Qi, who was from China but alone in Bonn to join
us for lunch, and afterwards she spent the day with us and his
wife, Astrid, visiting the Augustusburg Palace in Brühl.
Prof. Sauerbruch’s work on portal hypertension started in
Munich around the same time that he was working on his gall
stone projects. Together with his fellow hepatologists, he
published widely on topics related to treatment of bleeding
esophageal varices using sclerotherapy, the standard of care at
the time. He devised various techniques to measure the intra-
variceal pressure, such as ﬁne needle direct puncture technique
and a balloon technique, and correlated the pressure with endo-
scopic signs and severity of liver disease in patients [10]. His
expertise was called upon to help deﬁne and set standards in
methodology, and therapeutic strategies in portal hypertension
at the inaugural Baveno meeting on portal hypertension [11].
After moving to Bonn in 1992, his work on gallstones ceased,
and he concentrated his research on portal hypertension. Despite
heavy administrative duties as head of the Department of
Internal Medicine, he never neglected his research activities. It
was during this period that he devised many experiments,
manipulating the portal circulation in order to understand the
pathophysiology of portal hypertension. It was this common
interest in the pathophysiology of portal hypertension that
consolidated our friendship. There were many exchanges of ideas,
and I have been most amazed by his clear thinking, and his
innovative viewpoints. Therefore, it was no surprise when I saw
his publications on the novel use of transjugular intrahepatic
porto-systemic stent shunt (TIPS) as a treatment for hepatorenal
syndrome [12,13]. This set of experiments taught us that portal
hypertension is intricately involved in the pathogenesis of renal
dysfunction in cirrhosis. Prof. Sauerbruch then went on to manip-
ulate the portal circulation with different pharmacological agents
to further elucidate the mechanisms involved in the pathogenesis
of portal hypertension. Thus we see such original concepts of
using atorvastatin to inhibit the hepatic RhoA/Rho-kinase system
while simultaneously activating endothelial nitric oxide synthase
to induce a reduction in intrahepatic resistance, with a conse-
quent reduction in portal pressure [14]. Atorvastatin also
attenuates hepatic ﬁbrosis by decreasing hepatic stellate cell
turnover [15], further contributing to a reduction in intra-hepatic
resistance. Other pharmacological manipulations included the
use of irbesartan and losartan to attenuate portal hypertension
by counteracting the impaired vascular responsiveness of the
splanchnic vessels to alpha1-adrenoceptor agonists [16,17].
Using the same meticulous approach, he further extended his
investigations into the renal complications of cirrhosis. He
reported on the preservation of renal functional reserve in
patients with advanced cirrhosis and ascites [18]. He also docu-
mented that the use of low dose losartan was able to improve
the renal function in an experimental model of cirrhosis via the470 Journal of Hepatology 201inhibition of the intra-renal renin-angiotensin system [19]. This
provides a potential for maintaining renal function in cirrhosis
in situations where renal dysfunction can occur. Thus we see that
his investigations extend far into every aspect of portal hyperten-
sion, and his breadth of knowledge exceeds that of many of his
peers. A search in PubMed identiﬁes 694 articles that he has
authored or co-authored to date. All of this hard work always
comes back to his one aim: to improve the outcome of his
patients with cirrhosis and portal hypertension.
Despite his busy schedule, Prof. Sauerbruch always ﬁnds time
to be involved with the hepatology community. He was the
President of the German Society of Gastroenterology in 2001–2,
as well as of the President of the German Association for the
Study of the Liver in 2009–10. In addition, he has served as a
member of the editorial board of many prestigious journals such
as GUT, and the Journal of Hepatology. It is still a secret how he
ﬁnds time to ﬁt in his many commitments, as he has never failed
to spend time with his trainees. His former fellow, now Prof.
Michael Schepke, fondly remembers him as the mentor who
always challenged him with new ideas, and encouraged him to
try fresh approaches to ﬁnd answers to scientiﬁc questions.
Two other former trainees, now Prof. Jörg Heller and Dr Jonel
Trebicka, helped build up and now maintain his portal hyper-
tension laboratory. Their combined effort of more than 80
publications on various aspects of portal hypertension is a
testimony of their close working relationship. Of course Prof.
Sauerbruch humbly acknowledges that his work in portal
hypertension would not have ﬂourished without these young
individuals as the pillars in his laboratory. Prof. Schepke also
affectionately remembers Prof. Sauerbruch rushing home every
night on his bicycle, rolling downhill, never caring for red
lights, speed limits, nor one-way street directions, because there
is nothing more important to him than his family, especially his
grandson Pauli. We met Pauli in 2004, a gregarious child of
2 years, who very naturally hopped on my husband’s
shoulders for a ride on the way to dinner. Pauli has been Prof.
Sauerbruch’s pride and joy, and he spends his time teaching Pauli
to horse ride and to ice-skate. Of course Prof. Sauerbruch himself
is a brilliant ice skater, an accomplished equestrian, and an
expert skier.
Having spent his entire career as a successful academic physi-
cian, one would expect Prof. Sauerbruch to retire after completing
his 20-year term at the University of Bonn, and start enjoying his
time with his family and his friends. It seems that his energetic
personality does not allow him to stop working. He has just
completed his position as the Temporary Head of the Department
of Gastroenterology and Endocrinology, at the University of
Göttingen. I am sure he will stay in touch with his colleagues
and continue his efforts into new scientiﬁc enquiries. Congratula-
tions to Prof. Sauerbruch for having been awarded the EASL
Recognition Award. I count myself as being most privileged to
have known Prof. Sauerbruch and to follow him as a role model
in my academic endeavours.
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